NCT05329961View on ClinicalTrials.gov

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2028

Conditions
Human Papilloma Virus
Interventions
DRUG

Gardasil9

The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Boston Medical Center

OTHER

NCT05329961 - Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old | Biotech Hunter | Biotech Hunter